APEX1 and pancreatic neoplasm: In line with these findings, the application of novel analogues of both APE1/Ref-1 and CAIX inhibitors (namely APX2009, APX2014, and FC12-531A) with improved potency significantly affected pancreatic cancer cell survival [65].